About
Marking another positive step in the collaborative fight against cancer, GlaxoSmithKline (GSK) has released the genomic profiling data for over 300 cancer cell lines via the National Cancer Institute’s cancer Bioinformatics Grid™ (caBIG™). Cancer cell lines can be manipulated in the laboratory and have been used extensively by GSK in the discovery and development of novel cancer therapeutics. These data are available through caArray.Marking another positive step in the collaborative fight against cancer, GlaxoSmithKline (GSK) has released the genomic profiling data for over 300 cancer cell lines via the National Cancer Institute’s cancer Bioinformatics Grid™ (caBIG™). Cancer cell lines can be manipulated in the laboratory and have been used extensively by GSK in the discovery and development of novel cancer therapeutics. These data are available through caArray.
Openness
Data usage guidelines
This data set was generated and provided by GlaxoSmithKline. Any publication or presentation of results utilizing this data set will (i) include appropriate cell line sourcing reference (e.g. ECACC/HPACC, DSMZ, ATCC); (ii) catalogue reference number; and (iii) in the case of ECACC/HPACC acknowledge accurate reference to the work of the original depositor into ECACC/HPACC. The cell line sourcing reference and the catalog number are provided as Source Annotations in the Experiment and are additionally in the tab-delimited .SDRF file that is available as a Supplemental File with this experiment. The original depositor references are provided as Publications associated with this Experiment. Any publications or presentations generated from use of this data set should include appropriate acknowledgement to GSK.
